TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Position Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Disability Questionnaire (PDQ) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Central Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximally tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-to-full-recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and reactogenicity of TDENV-PIV formulations
Endpoint domain: Adverse events/effects
Primary endpoint: Humoral immunogenicity to DENV types
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease of Pseudomonas aeruginosa in Nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Change From Baseline in the Standard Photosensitivity Response (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Montgomery and Asberg Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic availability of Lysine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in the dependency on oxygen supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Myocardial glucose uptake (intrasubject before/after rosiglitazone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial glucose uptake (between insulin-resistant & insulin-sensitive groups)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in index knee pain with walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to End-Stage Renal Disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Time to achieve ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Low back-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measures of Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ranked Gravimetric Sweat Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Seropositive for Anti-HAV and Anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HAV and Anti-HBs Geometric Mean Concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV Vaccination Rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Subjective Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with treatment adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with plasmatic HIV viral load below 60 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Receptor Availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Drinking Behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean finger ischemia time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessment: Diabetes Quality of Life (DQoL) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: activity counts per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking time in minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking distance in meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of plaque morphology assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of in-vitro histology with in-vivo histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Serum Triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of response (LOR) during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Composite outcome of arterial or venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disseminated intravascular coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vibriocidal titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Depression severity (PHQ-9)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety severity (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate on the obstacle avoidance task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accrual Rate as a Measure of Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention as a measure of Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of adenitis favorable outcome at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Patient Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MADRS Score Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Frontal Activation During Emotional Stroop Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of vorinostat (SAHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RPTD) of SAHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of RESTEN-MP injection
Endpoint domain: Adverse events/effects
Primary endpoint: Hip flexor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Severity Rating (CSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients screened positive for NTM by the culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visit by LHWs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Amount of lateral tissue displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Intestinal Anastomotic Leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antimicrobial use in number of days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Phenotypic assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microglial activation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial coverage of the stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Experiencing Expected Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19-related hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Area Under Curve (AUC[0-12h])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax at Tmax and Cmin at Tmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax Normalized at Tmax and Cmin Normalized at Tmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence and estimated prevalence of HPV 6/11 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Spider Phobia Questionnaire (SPQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavioral Approach Test (BAT) steps
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Distress ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of culture confirmed influenza A and/or B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in insulin resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of eligible participants recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average Pain Score at target site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative local anesthetic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virologic Response at 12 weeks post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of the ACS catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in low-density lipoprotein (LDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Responses to the Control of Eating Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comorbidity of benign hypermobility joint syndrome and functional constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant free metastasis survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Meeting ACR20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp X-ray Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in the Disability Index of the HAQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Macular edema reduction or stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Indicated Unconfirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax, tmax, AUC of ivabradine and metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in glomerular filtration rate decline rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: histological degree of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived risk of melanoma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sun avoidance/protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin self-examination behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Metabolites Elevated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % phagocytes cells of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rectal Sensory Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global Longitudinal Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Prematurely Discontinued the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity (AUC0-inf) of Evobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration Observed (Cmax) of Evobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physical functional fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Metabolic Rate of Midazolam (CYP3A4) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disposition from Emergency Department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ED Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Subjects With Clinically Significant Abnormal Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuron-specific enolase (NSE) serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distance between anterior prosthesis and bladder neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients with Safe, Well-tolerated Moderate Intensity Respiratory Muscle Training (RMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Patients Able to Complete Respiratory Muscle Training (RMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of Change in Maximum Expiratory Pressure from Pre-test to Post-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Utilization of Primary Care Provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Relative accuracy of urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative accuracy of self-collected vaginal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Experiencing Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in score of Affective Lability Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in the score of the Affective Lability Item of the Zanarini Rating Scale for Borderline Personality Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Embolization success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop-out
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Suicidality (Suicide Attempts)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax (maximum measured concentration of BI 671800 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (area under the concentration time curve of BI 671800 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous and anterior chamber levels of prostaglandins and cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MADRS-6 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MADRS-10 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to End of Treatment in the MADRS-10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Diagnostic Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Objective Response (OR) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in essential fatty acid (EFA) status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in choline status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Intensity Score at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Slow Wave Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: correlation ratio between point-of-care PT/INR value and standard laboratory assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes